Lupin Share Price in Focus; Signs Deal with Visus Therapeutics to Sell YUVEZZI in Europe

Lupin has entered into a new deal with Visus Therapeutics Inc., U.S.A, that will give its Netherlands-based subsidiary VISUfarma B.V. exclusive rights to sell YUVEZZI in the European Union, the UK, Switzerland, Norway and Iceland, as per the exchange filings.  

YUVEZZI is a once-daily eye drop used for presbyopia, The product has already been approved by the US FDA.  

Lupin Gets Exclusive Rights in Europe 

Under the agreement, VISUfarma will handle the regulatory work as well as the marketing, promotion, distribution, and sale of YUVEZZI in the selected countries.  

The agreement will run country by country and can continue for up to 20 years from the first commercial sale of YUVEZZI in each country. Lupin's subsidiary can also renew the agreement for further five-year periods after that.  

Deal Can Be Worth Up to €75 Million 

The agreement includes a potential consideration of up to €75 million until the first commercial sales in the licensed markets. 

This includes a €20 million strategic investment in Visus or its parent company through a SAFE instrument. Another €55 million can be paid based on regulatory and commercial milestones. Lupin will also make royalty payments linked to net sales.  

YUVEZZI Targets Presbyopia 

YUVEZZI combines carbachol and brimonidine tartrate in a once-daily eye drop. 

The treatment is designed to improve near vision in people with presbyopia. According to the company, the condition affects nearly 2 billion people globally.   

Read More: Titagarh Rail Systems Share Price in Focus; Approved by Indian Railways as Vendor for 3 Phase Traction Motors! 

Lupin Share Price Performance 

As of August 20, 2026, at 12:09 PM, Lupin share price was trading at ₹2,220.50 per share, reflecting a decline of 0.5% from the previous trading session. 

Conclusion 

Lupin has signed an exclusive deal to market YUVEZZI in Europe, the UK, Switzerland, Norway and Iceland. The deal gives Lupin access to a new eye-care product while adding to its specialty medicines business.  

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.